Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA: 2011-2024

Historic EBITDA for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $16.1 million.

  • Veracyte's EBITDA rose 90.95% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 205.17%. This contributed to the annual value of $16.1 million for FY2024, which is 118.81% up from last year.
  • Latest data reveals that Veracyte reported EBITDA of $16.1 million as of FY2024, which was up 118.81% from -$85.8 million recorded in FY2023.
  • In the past 5 years, Veracyte's EBITDA ranged from a high of $16.1 million in FY2024 and a low of -$85.8 million during FY2023.
  • In the last 3 years, Veracyte's EBITDA had a median value of -$41.1 million in 2022 and averaged -$36.9 million.
  • As far as peak fluctuations go, Veracyte's EBITDA crashed by 180.89% in 2020, and later skyrocketed by 118.81% in 2024.
  • Veracyte's EBITDA (Yearly) stood at -$35.4 million in 2020, then crashed by 131.44% to -$81.9 million in 2021, then skyrocketed by 49.84% to -$41.1 million in 2022, then plummeted by 108.84% to -$85.8 million in 2023, then spiked by 118.81% to $16.1 million in 2024.